Compare IQ & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IQ | DRTS |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | China | Israel |
| Employees | N/A | 121 |
| Industry | Consumer Electronics/Video Chains | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 978.2M |
| IPO Year | 2017 | N/A |
| Metric | IQ | DRTS |
|---|---|---|
| Price | $1.15 | $12.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $2.91 | ★ $8.67 |
| AVG Volume (30 Days) | ★ 6.7M | 809.9K |
| Earning Date | 05-18-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.28 | N/A |
| Revenue Next Year | $3.54 | $699.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.95 | $2.87 |
| 52 Week High | $2.76 | $14.11 |
| Indicator | IQ | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 59.21 | 57.59 |
| Support Level | $0.99 | $6.59 |
| Resistance Level | $1.19 | $14.11 |
| Average True Range (ATR) | 0.06 | 0.87 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 86.66 | 57.77 |
Iqiyi is a leading streaming video-on-demand company in China that generates revenue mostly through a subscription basis. The platform also provides user-generated content to nonpaying users, monetized through ads. The company self-produces much of the subscription content and also generates revenue through content distribution, gaming, and IP licensing. Iqiyi competes directly with Tencent Video, Alibaba's Youku, ByteDance's MangoTV, and Bilibili. The company is 45% and 5% owned by Baidu and Xiaomi, respectively.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.